Skip to content

Phrenic Nerve and Diaphragm Electrophysiology in Pompe Disease

Electrophysiological Study of the Phrenic Nerve and Diaphragm in Pompe Disease: Retrospective and Prospective Cohort Analysis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07664930
Enrollment
20
Registered
2026-06-24
Start date
2026-03-30
Completion date
2029-02-28
Last updated
2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pompe Disease

Keywords

Pompe disease, Phrenic nerve, Diaphragm, Respiratory muscle weakness, Neuromuscular respiratory failure, Motor unit

Brief summary

Pompe disease is traditionally considered a lysosomal myopathy. However, increasing experimental and clinical evidence suggests involvement of the entire motor unit, including motor neurons, peripheral nerves, neuromuscular junctions, and skeletal muscle. Respiratory impairment is a major cause of morbidity and mortality, and diaphragm dysfunction is frequently observed. Clinical observations at IRCCS Fondazione Mondino have highlighted neurophysiological abnormalities of the phrenic nerve and diaphragm in patients with Pompe disease and respiratory involvement, sometimes occurring even in the absence of clinically significant limb muscle weakness. These findings suggest that respiratory motor unit dysfunction may represent an important component of the disease phenotype. This observational study aims to systematically characterize phrenic nerve conduction parameters and diaphragm electromyographic findings in adult patients with genetically confirmed Pompe disease and in patients with unexplained respiratory failure. Retrospective and prospective clinical, neurophysiological, and respiratory data collected during routine clinical care will be analyzed to explore whether phrenic nerve and diaphragm abnormalities may serve as markers of respiratory motor unit involvement in Pompe disease.

Detailed description

This is a non-interventional observational study with a mixed retrospective and prospective cohort design. No experimental treatments, additional diagnostic procedures, or study-specific interventions are introduced. All data derive exclusively from routine clinical evaluations performed as part of standard patient care. Two main populations are included: 1) Adult patients with genetically confirmed Pompe disease undergoing routine neurophysiological and respiratory assessments; 2) Patients with restrictive respiratory failure or unexplained hypoventilation who previously underwent phrenic nerve conduction studies and/or diaphragm electromyography as part of clinical workup, identified retrospectively. The retrospective component consists of systematic review of phrenic nerve conduction studies and diaphragm electromyography performed over previous years in patients with suspected neuromuscular respiratory failure. The prospective component involves standardized collection of neurophysiological and respiratory data obtained during routine follow-up of patients with confirmed Pompe disease. Neurophysiological assessments include bilateral phrenic nerve motor conduction studies and evaluation of peripheral nerves and limb muscles. Diaphragm needle electromyography is performed only when clinically indicated. Respiratory evaluations include spirometry with forced vital capacity in seated and supine positions, maximal inspiratory and expiratory pressures (MIP/MEP), and, when clinically required, overnight ventilation studies. The primary outcome is the characterization of phrenic nerve conduction parameters, including motor latency, compound muscle action potential amplitude, and presence or absence of diaphragmatic responses. Secondary outcomes include diaphragm electromyographic patterns, comparison between phrenic nerve and other peripheral nerves, and correlations between neurophysiological parameters and respiratory function. Data are collected retrospectively from medical records and prospectively during routine clinical visits, pseudonymized, and analyzed descriptively and exploratorily. The study aims to improve characterization of respiratory motor unit involvement in Pompe disease and to evaluate the potential diagnostic contribution of phrenic nerve and diaphragm electrophysiology in patients with unexplained respiratory failure.

Interventions

None listed

Sponsors

IRCCS National Neurological Institute "C. Mondino" Foundation
Lead SponsorOTHER
Fondazione Salvatore Maugeri
CollaboratorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

Age ≥ 18 years. For the prospective cohort: * Genetically confirmed diagnosis of Pompe disease. * Ability to undergo routine neurophysiological and respiratory assessments. * Written informed consent provided. For the retrospective cohort: * History of restrictive respiratory failure or unexplained hypoventilation. * Availability of previous phrenic nerve conduction studies and/or diaphragm electromyography performed as part of routine clinical evaluation.

Exclusion criteria

\- Age \< 18 years. For the prospective cohort: * Conditions preventing completion of neurophysiological assessments (e.g., inability to maintain required positioning or relevant clinical contraindications). * Known primary phrenic nerve injury (e.g., postsurgical phrenic palsy or documented traumatic phrenic neuropathy). * Presence of other neuromuscular disorders potentially confounding data interpretation. * Refusal or inability to provide informed consent. For the retrospective cohort: * Incomplete or technically non-interpretable neurophysiological examinations. * Previously established respiratory or neuromuscular diagnoses fully explaining respiratory impairment. * Cases requiring additional clinical information for study purposes when patient consent for contact or data completion cannot be obtained.

Design outcomes

Primary

MeasureTime frameDescription
Motor latency (ms)Baseline (at first available assessment, retrospective or prospective)Phrenic nerve conduction parameter measured by bilateral nerve conduction studies
Compound muscle action potential (CMAP) amplitude (millivolts)Baseline (at first available assessment, retrospective or prospective)Phrenic nerve conduction parameter assessed bilaterally by nerve conduction studies
Presence or absence of diaphragmatic responsesBaseline (at first available assessment, retrospective or prospective)Phrenic nerve conduction parameter assessed bilaterally

Secondary

MeasureTime frameDescription
Neurogenic patternBaseline (at time of clinical assessment when EMG is performed)Diaphragm electromyography pattern assessed when clinically indicated
Myopathic patternBaseline (at time of clinical assessment when EMG is performed)Diaphragm electromyography pattern assessed when clinically indicated
Mixed patternBaseline (at time of clinical assessment when EMG is performed)Diaphragm electromyography pattern assessed when clinically indicated
Normal patternBaseline (at time of clinical assessment when EMG is performed)Diaphragm electromyography pattern assessed when clinically indicated

Countries

Italy

Contacts

CONTACTGiuseppe Cosentino, MD
giuseppe.cosentino@mondino.it0382380249
CONTACTCinzia Fattore, MD
cinzia.fattore@unipv.it0382380385
PRINCIPAL_INVESTIGATORGiuseppe Cosentino, MD

Translational Neurophysiology

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 25, 2026